NIP
ALDX icon

Nicholas Investment Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Nicholas Investment Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-63,666
Closed -$371K – 284
2015
Q3 		$371K Buy
63,666
+22,878
+56% +$179K 0.03% 291
2015
Q2 		$317K Buy
40,788
+32,455
+389% +$280K 0.02% 301
2015
Q1 		$85K Buy
+8,333
New +$85K 0.01% 303

Other funds holding ALDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Nicholas Investment Partners's ALDX Position: Q4 2015 in Review

Nicholas Investment Partners sold out of Aldeyra Therapeutics (ALDX) in Q4 2015, closing a stake of 63,666 shares — an estimated $371K sold.

Nicholas Investment Partners first reported a position in ALDX in Q1 2015 and held it in 3 quarters. The position peaked at $371K in Q3 2015. 21 funds tracked by Wall St. Rank hold ALDX as of Q4 2015.

  • Nicholas Investment Partners reported no remaining Aldeyra Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Nicholas Investment Partners sold 63,666 Aldeyra Therapeutics shares in Q4 2015, an estimated $371K.
  • Nicholas Investment Partners first reported a position in Aldeyra Therapeutics in Q1 2015 and held it in 3 quarters.
  • Nicholas Investment Partners's Aldeyra Therapeutics position peaked at $371K in Q3 2015.
  • 21 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2015.

Based on Nicholas Investment Partners's 13F filing for Q4 2015, filed 12 Feb 2016.